These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31362777)

  • 1. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy.
    Tran TT; Mahajan A; Chiang VL; Goldberg SB; Nguyen DX; Jilaveanu LB; Kluger HM
    J Immunother Cancer; 2019 Jul; 7(1):200. PubMed ID: 31362777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
    Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM
    Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
    Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
    J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of brain metastases response to immunotherapy with pembrolizumab.
    Mahajan A; Goldberg SL; Weiss SA; Tran T; Singh K; Joshi K; Aboian MS; Kluger HM; Chiang VL
    J Neurooncol; 2024 Sep; 169(3):555-561. PubMed ID: 38963658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
    Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
    Goldstein DA; Ratain MJ; Saltz LB
    JAMA Oncol; 2020 Nov; 6(11):1694-1695. PubMed ID: 32459313
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.
    Addeo R; Zappavigna S; Luce A; Facchini S; Caraglia M
    Expert Opin Drug Saf; 2013 Sep; 12(5):729-40. PubMed ID: 23560594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
    Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
    Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.
    Hasegawa T; Yanagitani N; Utsumi H; Wakui H; Sakamoto H; Tozuka T; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Uchibori K; Kitazono S; Horiike A; Horai T; Kuwano K; Nishio M
    Anticancer Res; 2019 Dec; 39(12):6851-6857. PubMed ID: 31810952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perifocal edema volume is not associated with immunohistochemical features reflecting proliferation potential, microvessel density, neoangiogenesis and invasiveness in brain metastasis.
    Meyer HJ; Hamerla G; Höhn AK; Hoffmann KT; Surov A
    Clin Neurol Neurosurg; 2021 Mar; 202():106537. PubMed ID: 33571782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
    Chiarion Sileni V; Mandalà M; Queirolo P
    Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
    Gadgeel SM; Lukas RV; Goldschmidt J; Conkling P; Park K; Cortinovis D; de Marinis F; Rittmeyer A; Patel JD; von Pawel J; O'Hear C; Lai C; Hu S; Ballinger M; Sandler A; Gandhi M; Fehrenbacher L
    Lung Cancer; 2019 Feb; 128():105-112. PubMed ID: 30642441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
    Facchinetti F; Majori M; Sabato M; Gnetti L; Tiseo M
    Immunotherapy; 2019 Feb; 11(3):161-166. PubMed ID: 30730279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
    Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
    PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
    Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
    J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.